MX2010002053A - Composiciones de proteinas de fusion de notch humanizadas y metodos de tratamiento. - Google Patents

Composiciones de proteinas de fusion de notch humanizadas y metodos de tratamiento.

Info

Publication number
MX2010002053A
MX2010002053A MX2010002053A MX2010002053A MX2010002053A MX 2010002053 A MX2010002053 A MX 2010002053A MX 2010002053 A MX2010002053 A MX 2010002053A MX 2010002053 A MX2010002053 A MX 2010002053A MX 2010002053 A MX2010002053 A MX 2010002053A
Authority
MX
Mexico
Prior art keywords
subject
treating
treatment
compositions
methods
Prior art date
Application number
MX2010002053A
Other languages
English (en)
Inventor
Jan Kitajewski
Carrie Shawber
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of MX2010002053A publication Critical patent/MX2010002053A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)

Abstract

Esta invención proporciona una proteína de fusión que comprende un péptido de señalización, un dominio extracelular receptor de una proteína de Notch humana y una porción Fc de un anticuerpo enlazado ahí. Esta invención también proporciona un método para tratar a un sujeto que tiene un tumor, un método para inhibir la angiogénesis en un sujeto, un método para tratar a un sujeto que tiene cáncer ovárico y un método para tratar a un sujeto que tiene un desorden metabólico, que comprende administrar al sujeto una cantidad efectiva de la proteína de fusión antes mencionada para tratar al sujeto. Esta invención además proporciona usos de la proteína de fusión de arriba para la preparación de una composición farmacéutica para el tratamiento de un sujeto que tiene un tumor, para inhibir la angiogénesis en un sujeto, para tratar a un sujeto que tiene cáncer ovárico y para tratar a un sujeto que tiene un desorden metabólico.
MX2010002053A 2007-08-23 2008-08-22 Composiciones de proteinas de fusion de notch humanizadas y metodos de tratamiento. MX2010002053A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96605207P 2007-08-23 2007-08-23
PCT/US2008/010045 WO2009025867A2 (en) 2007-08-23 2008-08-22 Compositions of humanized notch fusion proteins and methods of treatment

Publications (1)

Publication Number Publication Date
MX2010002053A true MX2010002053A (es) 2010-07-28

Family

ID=40378882

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002053A MX2010002053A (es) 2007-08-23 2008-08-22 Composiciones de proteinas de fusion de notch humanizadas y metodos de tratamiento.

Country Status (15)

Country Link
US (2) US9127085B2 (es)
EP (1) EP2193143B1 (es)
JP (2) JP2010536855A (es)
KR (1) KR20100076947A (es)
CN (1) CN101883786A (es)
AU (1) AU2008289462B2 (es)
BR (1) BRPI0815291A2 (es)
CA (1) CA2697262A1 (es)
IL (2) IL204111A (es)
MX (1) MX2010002053A (es)
NZ (3) NZ600171A (es)
RU (1) RU2532830C2 (es)
SG (1) SG183763A1 (es)
WO (1) WO2009025867A2 (es)
ZA (1) ZA201001427B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
US8133857B2 (en) 2006-03-07 2012-03-13 The Brigham and Women's FHospital, Inc. NOTCH inhibition in the treatment of atherosclerosis
US9567396B2 (en) 2006-03-07 2017-02-14 Evonik Degussa Gmbh Notch inhibition in the prevention of vein graft failure
WO2011053822A2 (en) * 2009-11-01 2011-05-05 The Brigham And Women's Hospital, Inc. Notch inhibition in the treatment and prevention of obesity and metabolic syndrome
WO2007145840A2 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2009103637A1 (en) * 2008-02-22 2009-08-27 Vrije Universiteit Brussel Method for generating islet beta cells from dedifferentiated exocrine pancreatic cells
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
MX2011000233A (es) 2008-07-08 2011-05-19 Oncomed Pharm Inc Agentes de union del receptor notch1 y metodos para su uso.
KR20110074846A (ko) 2008-08-22 2011-07-04 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 노치３ 신호전달의 디코이 억제제로서의 인간 노치３ 기반 융합 단백질
EP2523682B1 (en) 2010-01-13 2015-12-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
AR088048A1 (es) * 2011-10-04 2014-05-07 Univ Columbia Señuelos notch1 humanos
AU2013348570B2 (en) 2012-11-21 2017-01-12 Pharmabcine Inc. Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition comprising same
US9944700B2 (en) 2013-03-13 2018-04-17 Novartis Ag Notch2 binding molecules for treating respiratory diseases
US20160030513A1 (en) * 2013-03-15 2016-02-04 The Trustees Of Columbia University In The City Of New York Notch1 Decoy Antagonists Protect From Obesity-Induced Insulin Resistance and Fatty Liver
WO2014151950A1 (en) * 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Notch1 decoy antagonists protect from obesity-induced insulin resistance and fatty liver
MX2017012615A (es) * 2015-04-16 2018-04-30 Eisai R&D Man Co Ltd Anticuerpo anti-notch4 humano.
WO2017205651A1 (en) * 2016-05-25 2017-11-30 The Trustees Of Columbia University In The City Of New York Human notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and dll-notch signaling
US11325957B2 (en) * 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
CN108707628B (zh) * 2018-05-28 2021-11-23 上海海洋大学 斑马鱼notch2基因突变体的制备方法
CN108753833B (zh) * 2018-05-28 2021-12-03 上海海洋大学 斑马鱼notch3基因突变体的制备方法
CN109467598B (zh) * 2018-11-28 2021-11-09 生命谷（海南）生物科技股份有限公司 肿瘤相关基因notch1突变短肽及其应用
US20230174633A1 (en) * 2020-03-30 2023-06-08 Memorial Sloan Kettering Cancer Center Methods and compositions for modulating lipid storage in adipose tissue
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用
CN114062682A (zh) * 2021-11-10 2022-02-18 厦门大学附属心血管病医院 Notch3作为检测靶标的应用
CN116790603B (zh) * 2023-08-18 2023-10-31 成都中科奥格生物科技有限公司 一种sgRNA、CRISPR/Cas9载体及其构建方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US6716974B1 (en) 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
FR2751986B1 (fr) 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
GB9623236D0 (en) * 1996-11-07 1997-01-08 Imperial College Notch
US6379925B1 (en) 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
GB9927328D0 (en) 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
AU2002339157A1 (en) * 2001-11-14 2003-05-26 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
EP1492816A2 (en) * 2002-04-05 2005-01-05 Lorantis Limited Modulators of the notch signalling pathway and uses thereof in medical treatment
EP1525221A1 (en) * 2002-08-03 2005-04-27 Lorantis Limited Conjugate of notch signalling pathway modulators and their use in medical treatment
JP2006515177A (ja) * 2002-09-10 2006-05-25 ロランティス リミテッド Ｎｏｔｃｈリガンドタンパク質を含む医薬組成物及び医学的処置
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
WO2006047878A1 (en) 2004-11-03 2006-05-11 British Columbia Cancer Agency Branch Cancer therapeutics and methods for their use
KR20080025761A (ko) * 2005-07-29 2008-03-21 더 제너럴 하스피탈 코포레이션 피부 손상을 감소시키는 방법 및 조성물
TW200824707A (en) * 2006-10-19 2008-06-16 Genentech Inc Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
KR20110074846A (ko) 2008-08-22 2011-07-04 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 노치３ 신호전달의 디코이 억제제로서의 인간 노치３ 기반 융합 단백질
AR088048A1 (es) 2011-10-04 2014-05-07 Univ Columbia Señuelos notch1 humanos

Also Published As

Publication number Publication date
RU2010110812A (ru) 2011-09-27
US20160115217A1 (en) 2016-04-28
KR20100076947A (ko) 2010-07-06
SG183763A1 (en) 2012-09-27
RU2532830C2 (ru) 2014-11-10
AU2008289462B2 (en) 2014-01-23
WO2009025867A2 (en) 2009-02-26
NZ618129A (en) 2015-05-29
EP2193143A2 (en) 2010-06-09
NZ600171A (en) 2014-01-31
EP2193143A4 (en) 2012-01-25
IL204111A (en) 2015-08-31
BRPI0815291A2 (pt) 2015-02-03
NZ583649A (en) 2012-06-29
CN101883786A (zh) 2010-11-10
WO2009025867A3 (en) 2009-12-30
AU2008289462A1 (en) 2009-02-26
JP2016040245A (ja) 2016-03-24
CA2697262A1 (en) 2009-02-26
ZA201001427B (en) 2011-05-25
US9127085B2 (en) 2015-09-08
US20110008342A1 (en) 2011-01-13
IL220723A0 (en) 2012-08-30
JP2010536855A (ja) 2010-12-02
EP2193143B1 (en) 2016-06-08

Similar Documents

Publication Publication Date Title
MX2010002053A (es) Composiciones de proteinas de fusion de notch humanizadas y metodos de tratamiento.
MX2011001805A (es) Proteinas de fusion humanas basadas en notch3 como inhibidores de señuelo de la señalizacion de notch3.
NZ590131A (en) Notch-binding agents and antagonists and methods of use thereof
UA94899C2 (ru) Фиксированное дозирование антител к her
WO2008091641A3 (en) Compositions and methods for diagnosing and treating cancer
WO2012135854A3 (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
MX349198B (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
WO2007145840A3 (en) Compositions and methods for diagnosing and treating cancer
NZ607710A (en) 4-1bb binding molecules
MX2018010331A (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos.
WO2010019702A3 (en) Ddr1-binding agents and methods of use thereof
EA201270365A1 (ru) Молекулы анти-gcc антитела и соответствующие композиции и способы
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
MX353319B (es) Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.
MX2015000565A (es) Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos.
MX355181B (es) Anticuerpos humanos contra el factor tisular.
UA117807C2 (uk) ІМУНОКОН'ЮГАТ, ЩО МІСТИТЬ РЕКОМБІНАНТНЕ АНТИТІЛО ДО РЕЦЕПТОРА ЕПІДЕРМАЛЬНОГО ФАКТОРА РОСТУ ЛЮДИНИ (hEGFR), ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЯКА ЙОГО МІСТИТЬ
WO2017060322A3 (en) Ptefb-inhibitor-adc
MA32288B1 (fr) Nouveaux anticorps utiles pour le traitement du cancer
WO2008142303A3 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
WO2011063237A3 (en) Jagged-binding agents and uses thereof
SI2125897T1 (en) MONOCOLONIAL PROTITELES AGAINST GT 468 FOR CARRYING CANCER
WO2008070090A3 (en) Compositions and methods for diagnosing and treating cancer
WO2008042941A3 (en) Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
TN2012000151A1 (en) Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration